NCT02883049
|
Phase III |
Dasatinib
Dexamethasone + Doxorubicin
Prednisone
Vincristine
Thioguanine
Cytarabine
Mercaptopurine
Leucovorin
Methotrexate
Pegaspargase
Etoposide
Clofarabine
|
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations |
Recruiting |
NCT02112916
|
Phase III |
Cyclophosphamide
Vincristine
Ifosfamide
Pegaspargase
Methotrexate
Cytarabine
Mercaptopurine
Thioguanine
Leucovorin
Daunorubicin
Dexamethasone
Bortezomib
Etoposide
Doxorubicin
|
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma |
Suspended |
NCT03007147
|
Phase III |
Pegaspargase
Methotrexate
Leucovorin
Cytarabine
Mercaptopurine
Thioguanine
Vincristine
Cyclophosphamide
Imatinib
Ifosfamide
dexrazoxane
Daunorubicin
Dexamethasone
Methylprednisolone
Etoposide
Prednisolone
Doxorubicin
|
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia |
Recruiting |
NCT03117751
|
Phase II |
Cyclophosphamide
Vincristine
Idarubicin
Blinatumomab
Doxorubicin
Clofarabine
Vorinostat
Ruxolitinib
Prednisone
Bortezomib
Etoposide
Dasatinib
Daunorubicin
Dexamethasone
Rituximab
Methotrexate
Cytarabine
Mercaptopurine
Pegaspargase
|
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma |
Recruiting |
NCT02535806
|
Phase II |
Vincristine
Bortezomib
Pegaspargase
Methotrexate
Cytarabine
Mitoxantrone
Prednisone
|
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults |
Terminated |
NCT03571321
|
Phase I |
Pegaspargase
Methotrexate
Cytarabine
Mercaptopurine
Thioguanine
Ruxolitinib
Cyclophosphamide
Dexamethasone
Vincristine
Rituximab
Doxorubicin
|
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia |
Not yet recruiting |
NCT01523977
|
Phase I |
Prednisone
Everolimus
Vincristine
Doxorubicin
Pegaspargase
|
Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL |
Active, not recruiting |
NCT02043587
|
Phase II |
Rituximab
Pegaspargase
Methotrexate
Cytarabine
Leucovorin
Cyclophosphamide
Dasatinib
Daunorubicin
Vincristine
Etoposide
|
Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma |
Active, not recruiting |
NCT02419755
|
Phase II |
Cytarabine
Mercaptopurine
Methotrexate
Pegaspargase
Vorinostat
Doxorubicin
Bortezomib
Dexamethasone
Mitoxantrone
Prednisone
|
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies |
Terminated |
NCT02518750
|
Phase II |
Panobinostat + Bortezomib + Dexamethasone
Pegaspargase
Mercaptopurine
Nelarabine
Mitoxantrone
Vincristine
Cyclophosphamide + Etoposide
Cytarabine + Methotrexate + Prednisone
Clofarabine
|
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma |
Terminated |
NCT01483690
|
Phase Ib/II |
Pegaspargase
Methotrexate
Dexamethasone
Vincristine
Decitabine
Mitoxantrone
|
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL |
Terminated |
NCT02553460
|
Phase II |
Cyclophosphamide
Mitoxantrone
Dexamethasone
Bortezomib
Etoposide
Vincristine
Pegaspargase
Vorinostat
Cytarabine
Methotrexate
Leucovorin
|
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I |
Recruiting |
NCT03020030
|
Phase III |
Nelarabine
dexrazoxane
Asparaginase
Vincristine
Cyclophosphamide
Cytarabine
Mercaptopurine
Pegaspargase
Methotrexate
Etoposide
Doxorubicin
Dexamethasone
Prednisone
Dasatinib
Leucovorin
|
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents |
Recruiting |